Ghosh, Shrestha
Raundhal, Mahesh http://orcid.org/0000-0001-8175-2957
Myers, Samuel A.
Carr, Steven A. http://orcid.org/0000-0002-7203-4299
Chen, Xi http://orcid.org/0000-0002-7995-6202
Petsko, Gregory A. http://orcid.org/0000-0003-3668-3694
Glimcher, Laurie H. http://orcid.org/0000-0002-4971-0404
Funding for this research was provided by:
Dana-Farber Cancer Institute
DH | NIHR | Health Services Research Programme
The Pussycat Foundation
Article History
Received: 9 May 2021
Accepted: 25 October 2021
First Online: 22 December 2021
Competing interests
: L.H.G. is a former Director of Bristol-Myers Squibb and the Waters Corporation and currently serves on the Board of Directors of GlaxoSmithKline Pharmaceuticals and Analog Devices and on the scientific advisory boards of Repare Therapeutics, Abpro Therapeutics and Kaleido Therapeutics. G.A.P. is on the Scientific Advisory Boards of Amicus Therapeutics, MeiraGTx, Annovis Bio, Retromer Therapeutics and Proclara Biosciences and holds equity or stock options in Denali Therapeutics, MeiraGTx, Annovis Bio, Retromer Therapeutics and Proclara Biosciences, companies that are developing therapies for neurodegenerative diseases. M.R. is currently an employee at Jnana Therapeutics. The other authors declare no competing interests.